Cancer drug sales are on track to post an impressive compound annual growth rate of 11.4% over the next five years, according to a report by EvaluatePharma. This double-digit growth rate is particularly noteworthy because cancer drug sales already dwarf all other pharma market segments by a wide...

LEXINGTON, Mass., Sept. 30, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1 and cancer vaccines, announced today that Jennif...

Today, we want to share our analysis of Agenus ( AGEN ) with you. Over the last year, its stock fluctuated largely, falling from ~$3.67 in January 2019 to ~$2.6 in August 2019. Recently, the company’s stock price grew by over 15%, driven by the IND acceptance for AGEN2373. The company...